Topline data were announced from two phase 3 trials evaluating deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in adults with active psoriatic arthritis (PsA). POETYK PsA-1 (ClinicalTrials.gov ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback